Jorveza

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0020/G	This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition	24/11/2022	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
II/0015	Update of section 4.8 of the SmPC in order to update the list of adverse reactions based on final results from the long-term maintenance study BUL-2/EER; this is a double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 3.0 has also been submitted. The MAH also submitted the final report of study BUL-6/BIO, which was previously assessed within the scope of extension EMEA/H/C/004655/X/0007/G as applicant's response to CHMP Day 120 List of Questions. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	10/11/2022		SmPC and PL	The applicant has submitted the final study report of study BUL-2/EER and evaluated the safety of the different phases of the trial separately. Overall, the conclusions of the applicant that the nature and frequency of AEs over time, during the overall 3-year observation period is consistent with the known safety profile of the previous data submitted (mainly the OLI and DB phases of the trial) has been demonstrated in adequate manner. As already previously demonstrated, the main safety concern with the compound relates to the occurrence of local fungal infections in the oral cavity, the laryngeal and pharyngeal regions, as well as the oesophagus. Most of the other events observed relate to known events for the substance budesonide, which, however, do not seem to occur at increased frequency or severity in the patients with EoE with the formulation under evaluation. The applicant has, however, identified a couple of adverse effects/adverse drug reactions, which are – based on the results of the final study report of study BUL-2/EER – proposed to be included into the prescribing information for the product in addition, or with a higher frequency than previously assigned. The conclusion to add several identified ADRs into the prescribing information is overall supported, and adequate frequency of these events has been assigned. Overall, it can be concluded that the treatment with Jorveza at daily doses of 0.5 mg or 1.0 mg has been

					demonstrated to have an acceptable safety profile also in long-term treatment beyond one year, and that this safety profile is not relevantly differing from the safety profile identified in short-term treatment or long-term treatment up to one year. The risk-benefit ratio of the compound remains positive.
R/0016	Renewal of the marketing authorisation.	21/07/2022	27/09/2022	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Jorveza in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Only editorial changes to the Product Information are requested at the time of renewal.
IB/0017/G	This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	07/06/2022	n/a		
PSUSA/10664 /202107	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products	10/02/2022	n/a		PRAC Recommendation - maintenance

	indicated for eosinophilic esophagitis only)				
N/0014	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/01/2022	27/09/2022	PL	
PSUSA/10664 /202101	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products indicated for eosinophilic esophagitis only)	16/09/2021	15/11/2021	SmPC and PL	Please refer to EMEA/H/C/PSUSA/00010664/202101 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
IA/0012/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites	25/05/2021	n/a		
PSUSA/10664 /202007	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products indicated for eosinophilic esophagitis only)	11/02/2021	n/a		PRAC Recommendation - maintenance
PSUSA/10664 /202001	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products indicated for eosinophilic esophagitis only)	03/09/2020	n/a		PRAC Recommendation - maintenance
X/0007/G	This was an application for a group of variations. - Extension of application to include a new strength 0.5 mf orodispersible tablet - Extension of indication to include the maintenance	26/03/2020	20/05/2020	SmPC, Labelling and PL	Please refer to the scientific discussion: Jorveza EMEA/H/C/004655/X/0007/G

	of remission for Jorveza (0.5 mg and 1 mg orodispersible tablets); as a consequence, sections 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated to reflect the recommended daily dose and duration of treatment of Jorveza for the maintenance of remission, to update the list of adverse reactions and the clinical efficacy and safety information based on the results of the phase III clinical study BUL-2/EER. The relevant sections of the package leaflet are updated accordingly. In addition, a revised RMP (version 2.1) has been submitted to reflect the results of this study and to align with the GVP Module V (rev 2) template. The MAH also took the opportunity to bring the product information in line with the latest QRD template (version 10.1). - To add a new pack-size of 200 x 1 orodispersible tablets (unit dose) in a blister for Jorveza 1 mg orodispersible tablet (EU/1/17/1254/006) Annex I_2.(c) Change or addition of a new strength/potency B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
PSUSA/10664 /201907	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products	16/01/2020	n/a		PRAC Recommendation - maintenance

	indicated for eosinophilic esophagitis only)				
PSUSA/10664 /201901	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products indicated for eosinophilic esophagitis only)	11/07/2019	n/a		PRAC Recommendation - maintenance
IA/0006	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	14/06/2019	n/a		
N/0005	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	28/05/2019	20/05/2020	PL	
IA/0004	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	29/04/2019	n/a		
IB/0002	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	29/01/2019	n/a		
PSUSA/10664 /201807	Periodic Safety Update EU Single assessment - budesonide (for centrally authorised products indicated for eosinophilic esophagitis only)	17/01/2019	n/a		PRAC Recommendation - maintenance